ReviewTrends in cancer2024
Immunotherapy for colorectal cancer: insight from inherited genetics.
Review in Trends in cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Targeting USP8 with odoroside A regulates LXRβ-mediated fatty acid metabolic reprogramming against colorectal cancer.Acta pharmacologica Sinica · 2026Article
- A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy.Precision radiation oncology · 2026Review
- Decoding the Oncogenic Role of GNG10 in Colorectal Cancer: A Non-Canonical Wnt Pathway-Driven Mechanism.Journal of cellular and molecular medicine · 2026Article
- Arid3b suppresses CD8 + T cell infiltration and function in microsatellite-stable colorectal cancer via Runx3.Nature communications · 2026Article
- Hsa_circ_0007158 promotes colorectal cancer progression via the ceRNA axis and its association with immune infiltration.Cancer cell international · 2026Article
- Vaccinia virus armed with IL-21 can cure murine colorectal cancer liver metastases via intravenous administration.Journal for immunotherapy of cancer · 2026Article
- Genetic variants in VEGF gene family enhance colorectal cancer susceptibility via modulating metabolic pathways.Archives of toxicology · 2026Article
- Microsystem technologies for accelerating the discovery and translation of immunotherapies.Nature reviews. Drug discovery · 2026Review
- Tumour chemotherapy sensitivity test may predict clinical outcomes in colorectal cancer patients receiving oxaliplatin and fluoropyrimidine-based regimens.World journal of gastrointestinal oncology · 2025Article
- Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.Acta pharmaceutica Sinica. B · 2025Review
- TPD52 promotes the proliferation and metastasis of gastric cancer cells.BMC gastroenterology · 2025Article
- Brassinin from Brassica campestris L. inhibits colorectal cancer by inducing p62/NRF2/GPX4-regulated ferroptosis.Animal models and experimental medicine · 2025Article
- Computational analysis of DEHP's oncogenic role in colorectal cancer.Discover oncology · 2025Article
- A Novel Mitochondria-Associated Programmed Cell Death-Related Prognostic Model and Validation of Oncogene INHBB in Colorectal Cancer.International journal of genomics · 2025Article
- Analysis of risk factors and prognostic prediction in advanced colorectal cancer undergoing immunotherapy combined with targeted therapy.Frontiers in medicine · 2025Article
- A PET-CT radiomics model for immunotherapy response and prognosis prediction in patients with metastatic colorectal cancer.Frontiers in oncology · 2025Article
- Natural compounds modulate the mechanism of action of tumour-associated macrophages against colorectal cancer: a review.Journal of cancer research and clinical oncology · 2024Review
- Preferential activation of type I interferon-mediated antitumor inflammatory signaling by CuS/MnOJournal of nanobiotechnology · 2024Article
- Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy shows efficacy for multiple cancer types and potential for expanded use. However, current immune checkpoint inhibitors (ICIs) are ineffective against microsatellite-stable colorectal cancer (CRC), which is more commonly diagnosed. Immunotherapy strategies for non-responsive CRC, including new targets and new combination therapies, are being tested to address this need. Importantly, a subset of inherited germline genetic variants associated with CRC risk are predicted to regulate genes with immune functions, including genes related to existing ICIs, as well as new potential targets in the major histocompatibility complex (MHC) region and immunoregulatory cytokines. We review discoveries in the inherited genetics of CRC related to the immune system and draw connections with ongoing developments and emerging immunotherapy targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.